Times subject to small changes based on the final event production

27th Annual Prostate Cancer Foundation Scientific Retreat

October 22 - 23, 2020
AGENDA

Thursday, October 22, 2020
*All times in U.S. PDT

VIRTUAL POSTER SESSION

Starting on Tuesday October 20, 2020, 12:01 AM U.S. PDT

GENERAL SESSIONS

Welcome and Opening Remarks
7:00 AM - 7:05 AM

Howard Soule, PhD
Prostate Cancer Foundation

Session 1: Prostate Cancer, Androgens and COVID-19
7:05 AM - 8:05 AM

Moderator: Nima Sharifi, MD
Cleveland Clinic

Introduction
Nima Sharifi, MD
Cleveland Clinic

Regulation and Targeting of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2 in Human Airway Epithelial Cell Subtypes
Arul Chinnaian, MD, PhD
University of Michigan; Michigan Center for Translational Pathology

Randomized Clinical Trial of Camostat vs. Placebo in COVID-19 Outpatients
Joseph Vinetz, MD
Yale University

Hormonal Intervention for the Treatment of Veterans with COVID-19 Requiring Hospitalization (HITCH)
Matthew Rettig, MD
University of California, Los Angeles; VA Greater Los Angeles Healthcare System

Live Session Discussion
Thursday, October 22, 2020

Session 2: Circulating DNA Methylation Biomarkers for Diagnosis, Prognosis and Treatment Selection

8:10 AM - 9:10 AM

Moderator: Gerhardt Attard, MD, PhD
University College London Cancer Institute, UK

Introduction
Gerhardt Attard, MD, PhD
University College London Cancer Institute, UK

Using 5-hydroxymethylcytosine Sequencing to Interrogate Biological Drivers of Advanced Prostate Cancer
Martin Sjöström, MD, PhD
University of California, San Francisco

Opportunities for Tracking the Prostate Cancer Methylome in Plasma
Gerhardt Attard, MD, PhD
University College London Cancer Institute, UK

Circulating Methylation Biomarkers for Neuroendocrine Prostate Cancer Differentiation
Francesca Demichelis, PhD
University of Trento, Italy

Live Session Discussion

9:10 AM - 9:15 AM

Please Return to the Virtual Lobby to Join the Next Session
SPECIAL LECTURE
9:15 AM - 9:38 AM

Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer

Jean-Philippe Theurillat, MD
Institute of Oncology Research, Switzerland

Introduced by Prof. Mark Rubin, MD
University of Bern, Switzerland

Live Discussion

SPECIAL LECTURE
9:38 AM - 9:53 AM

A Community Resource of Genetically-Engineered Mouse Models that Recapitulate the Phenotypic Spectrum of Prostate Cancer

Cory Abate-Shen, PhD
Columbia University Irving Medical Center

Live Discussion
SPECIAL LECTURE
9:53 AM - 10:15 AM

The Genomic Evolution of Prostate Cancer

Paul Boutros, PhD, MBA
University of California, Los Angeles

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

Live Discussion

10:15 AM - 10:45 AM BREAK
Please Return to the Virtual Lobby to Join the Next Session

KEYNOTE ADDRESS
10:45 AM - 11:50 AM

Michael Milken
Founder and Chairman
Prostate Cancer Foundation

Introduced by Stuart Holden, MD
Prostate Cancer Foundation

11:50 AM - 11:55 AM Please Return to the Virtual Lobby to Join the Next Session
Thursday, October 22, 2020

**DEBATE:**

*Prostate Cancer Genomic Classifiers; Are We Ready for Prime Time?*

**11:55 AM - 12:40 PM**

**Moderators:**

- Felix Feng, MD (University of California, San Francisco)
- Rana McKay, MD (University of California, San Diego)

**Speakers:**

- **Pro:** Daniel Spratt, MD (University of Michigan)
- **Con:** Daniel Lin, MD (University of Washington)

**Live Discussion**

**12:40 PM - 12:45 PM** Please Return to the Virtual Lobby to Join the Next Session

**Session 3: Targeting MYC, the Emperor of Oncoproteins**

**12:45 PM - 2:00 PM**

**Moderator:** Sarki Abdulkadir, MD, PhD
Northwestern University

**Introduction**

Sarki Abdulkadir, MD, PhD
Northwestern University

**MYC and the Tumor Immune Microenvironment**

Dean Felsher, MD, PhD
Stanford University

**Advances in MYC Therapeutic Targeting in Cancer**

Rosalie Sears, PhD
Oregon Health & Science University
N-Myc as a Driver of Lineage Plasticity in Advanced Prostate Cancer
David Rickman, PhD
Weill Cornell Medicine

Small-Molecule MYC Inhibitors
Sarki Abdulkadir, MD, PhD
Northwestern University

Live Session Discussion
2:00 PM - 2:05 PM Please Return to the Virtual Lobby to Join the Next Session

SPECIAL LECTURE
2:05 PM - 2:35 PM

Current Challenges in Treatment of Patients with Metastatic Prostate Cancer
Himisha Beltran, MD
Harvard: Dana Farber Cancer Institute

Introduced by Rana McKay, MD
University of California, San Diego

Live Discussion

PCF Press:
Highlights from Day 1 and Look Forward at Day 2
2:35 PM - 2:45 PM

Karen Knudsen, PhD
Thomas Jefferson University

END DAY ONE
PANEL DISCUSSION:

Prostate Cancer Disparities: Lessons from the COVID-19 Era

7:00 AM – 8:00 AM

Moderator: Brandon Mahal, MD
University of Miami

Panelists:
Erin Kobetz, PhD, MPH (University of Miami)
Monica Baskin, PhD (University of Alabama at Birmingham)
Thomas Farrington (Prostate Health Education Network)
Randy Vince Jr., MD (University of Michigan)

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

Live Discussion

8:00 AM - 8:05 AM  Please Return to the Virtual Lobby to Join the Next Session

Session 4: Late Breaking Clinical Data for Prostate Cancer Patients
8:05 AM - 9:20 AM

Moderators: Howard Soule, PhD
Prostate Cancer Foundation

Introduction
Howard Soule, PhD
Prostate Cancer Foundation
Combinatorial Targeting of AR and AKT with Abiraterone and Ipatasertib for mCRPC with and without PTEN loss: The Ipetential150 Phase 3 Trial
Johann de Bono, MD, PhD
The Institute of Cancer Research; Royal Marsden Hospital, London, UK

Phase 1 Clinical Profile of AMG 160, a Half-Life Extended PSMA Bispecific T-cell Engager (BiTE®) Immunotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer
Matthew Rettig, MD
University of California, Los Angeles; VA Greater Los Angeles Healthcare System

Phase 1 Study of AMG 509, a STEAP1 x CD3 T Cell–Recruiting XmAb® 2+1 Immune Therapy, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Wm. Kevin Kelly, DO
Sidney Kimmel Medical College at Thomas Jefferson University; Sidney Kimmel Cancer Center

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Prostate Cancer
Dimitris Skokos, PhD
Regeneron Pharmaceuticals
Elizabeth Miller, MD
Regeneron Pharmaceuticals

Live Session Discussion

9:20 AM - 9:25 AM Please Return to the Virtual Lobby to Join the Next Session
Session 5: Microbiome and Cancer  
9:25 AM - 10:25 AM

Moderator: Ellen Filvaroff, PhD  
Bristol Myers Squibb

Introduction  
Ellen Filvaroff, PhD  
Bristol Myers Squibb

The Plasticity of the Microbiome in Colorectal Cancer  
Christian Jobin, PhD  
University of Florida

Host-Microbiome Interactions in Human Cancer  
Ran Blekhman, PhD  
University of Minnesota

Gut Microbiota and Cancer Immunotherapy  
Andrew Y. Koh, MD  
University of Texas Southwestern Medical Center

Live Session Discussion

10:25 AM - 10:55 AM BREAK  
Please Return to the Virtual Lobby to Join the Next Session
SPECIAL LECTURE
10:55 AM - 11:30 AM

State of the Science 2020
Jonathan W. Simons, MD
Prostate Cancer Foundation

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

11:30 AM - 11:35 AM Please Return to the Virtual Lobby to Join the Next Session

SPECIAL LECTURE
11:35 AM - 11:50 AM

VA-PCF Collaboration: Streamlined Genetic Sequencing in Veterans for Improved Clinical Care and Research Opportunities
Julie Graff, MD
VA Portland Health Care System

Introduced by Rebecca Levine
Prostate Cancer Foundation
Times subject to small changes based on the final event production

Friday, October 23, 2020

SPECIAL LECTURE
11:50 AM - 12:15 PM

A Polygenic Risk Score for Predicting Prostate Cancer in Men of African Descent

Christopher Haiman, ScD
Center for Genetic Epidemiology and Norris Comprehensive Cancer Center, University of Southern California

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

Live Discussion

12:15 PM - 12:20 PM Please Return to the Virtual Lobby to Join the Next Session

Session 6: Advances for Immunotherapy in Prostate Cancer
12:20 PM - 1:15 PM

Moderator: Howard Soule, PhD
Prostate Cancer Foundation

Introduction
Howard Soule, PhD
Prostate Cancer Foundation

Clinical Development of PSCA-Targeted CAR T Cells for Advanced Prostate Cancer
Tanya Dorff, MD
City of Hope

Co-expression of a Novel TGFβR Dominant Negative Receptor to Enhance PSMA Chimeric Antigen Receptor Therapy in the Treatment of Castrate Resistant Prostate Cancer Patients
Naomi Haas, MD
University of Pennsylvania
Development of a First-in-Class Shared Neo-Antigen Vaccine for the Treatment of Prostate Cancer
M. Alejandro Sepulveda, PhD
Janssen Research & Development, LLC

Live Discussion

1:15 PM - 1:20 PM  Please Return to the Virtual Lobby to Join the Next Session

Session 7: Recent Advances in Antibody-Drug Conjugates for the Treatment of Cancer
1:20 PM - 2:30 PM

Moderator: Marco Gottardis, PhD
Janssen Research & Development, LLC

Introduction
Marco Gottardis, PhD
Janssen Research & Development, LLC

Antibody Drug Conjugates: From Early Stage Research to Clinically Approved Drugs
Peter Senter, PhD
Seattle Genetics

Novel Approaches to Development of Antibody-Drug Conjugates for the Treatment of Cancer
Yuuri Hashimoto, PhD
Daiichi Sankyo Co., Ltd.

PSMA Antibody Targeted Amanitin Conjugate (PSMA-ATAC): Introducing a Novel Mode of Action into Prostate Cancer Therapy
George Badescu, PhD
Heidelberg Pharma AG

Live Session Discussion
Friday, October 23, 2020

**Closing Remarks**
2:30 PM - 2:35 PM

Howard Soule, PhD
Prostate Cancer Foundation

Jonathan W. Simons, MD
Prostate Cancer Foundation

END DAY TWO
MEETING ADJOURNED
Program Committee:

Program Committee Co-Chair: Howard Soule, PhD (Prostate Cancer Foundation)  
Program Committee Co-Chair: Andrea Miyahira, PhD (Prostate Cancer Foundation)

Jonathan W. Simons, MD (Prostate Cancer Foundation)  
Sarki Abdulkadir, MD, PhD (Northwestern University)  
Gerhardt Attard, MD, PhD (University College London Cancer Institute)  
Felix Feng, MD (University of California, San Francisco)  
Ellen Filvaroff, PhD (Bristol Myers Squibb)  
Marco Gottardis, PhD (Janssen Pharmaceuticals)  
Brandon Mahal, MD (University of Miami)
We deeply thank our Retreat supporters for providing funding for this educational initiative.